sodium thiosulfate (BYON5667)
/ Byondis
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
December 15, 2023
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
(clinicaltrials.gov)
- P1/2 | N=48 | Completed | Sponsor: Byondis B.V. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ Apr 2023
Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
November 03, 2022
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
(clinicaltrials.gov)
- P1/2 | N=48 | Active, not recruiting | Sponsor: Byondis B.V. | Recruiting ➔ Active, not recruiting | N=196 ➔ 48
Enrollment change • Enrollment closed • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2
August 04, 2022
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
(clinicaltrials.gov)
- P1/2 | N=196 | Recruiting | Sponsor: Byondis B.V. | Active, not recruiting ➔ Recruiting | N=48 ➔ 196
Enrollment change • Enrollment open • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2
August 03, 2022
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
(clinicaltrials.gov)
- P1/2 | N=48 | Active, not recruiting | Sponsor: Byondis B.V. | Recruiting ➔ Active, not recruiting | N=180 ➔ 48
Enrollment change • Enrollment closed • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2
January 27, 2022
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
(clinicaltrials.gov)
- P1/2 | N=180 | Recruiting | Sponsor: Byondis B.V. | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2021 ➔ Jan 2022
Enrollment open • Trial initiation date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2
July 30, 2021
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
(clinicaltrials.gov)
- P1/2; N=180; Not yet recruiting; Sponsor: Byondis B.V.
New P1/2 trial • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2
1 to 6
Of
6
Go to page
1